Document:

Exhibit 10.44

 

Exhibit 10.44

First Amendment

To French Annex

     Whereas, the Board of Directors of IDM Pharma, Inc. (the “Company”) has determined
that it is in the best interests of the Company to amend the terms of the French Annex to the
Company’s 2000 Stock Plan to provide that the lock-up period described in Section 11 of the French
Annex shall not apply where the optionee exercises his or her option during any permitted
post-termination exercise period that follows his or her termination of service.

     Accordingly, Section 11 of the French Annex is hereby amended and restated in its
entirety as follows, effective as of December 19, 2005:

Lock-Up Period. In the event of an exercise of Qualified Options prior to the
fourth
(4th) anniversary of the Date of Grant1, any shares of Common
Stock received upon exercise of such Qualified Options shall be held in a separate account
with a Company approved brokerage firm and may not be sold, assigned, donated or otherwise
disposed of until the fourth (4th) anniversary of the Date of Grant1.
However, this “Lock-Up Period” shall not apply in the case of death or disability (as
defined under in the second and third categories of Articles L 341-4 of the French social
security code) of the Optionholder. In addition, in the event of retirement or dismissal
(as both terms are defined under applicable law) of the Optionholder, the Lock-Up Period
shall not apply to any shares of Common Stock received upon exercise of Qualified Options,
provided that the relevant Options were exercised at least three months prior to the date of
retirement or dismissal, as the case may be. Notwithstanding the foregoing, the Lock-Up
Period shall not apply to any shares of Common Stock received upon exercise of Qualified
Options, provided that the relevant Options were exercised after the date of the termination
of the Optionholder’s Continuous Service in accordance with Article 6(h) of the Plan.
Additionally, the Board shall have the discretionary authority to extend, accelerate or
reduce any Lock-Up Period.

 

			
	1	 	The sale of the shares resulting from the
exercise of the options can not be restricted for a period longer than three
years as from the date of the exercise of the option. Therefore, in order that
the lock-up period is four years from the date of the grant, it should be
ensured that the options can not be vested during the first year from the date
of the grant.

1.Exhibit 10.49

 

Exhibit 10.49

***Text Omitted and Filed Separately
Confidential Treatment
Requested
Under 17 C.F.R. §§ 200.80(b)(4)
and
240.24b-2(b)(1)

ASSET PURCHASE AGREEMENT

BETWEEN

IDM PHARMA, INC.

AND

PHARMEXA INC.

NOVEMBER 23, 2005

 

 

ASSET PURCHASE AGREEMENT

     ASSET PURCHASE AGREEMENT, dated, November 23, 2005, by and between IDM Pharma, Inc., a
Delaware corporation (“Seller”), and Pharmexa Inc., a Delaware corporation
(“Buyer”).

Preliminary Statement

     WHEREAS, Seller wishes to sell and Buyer wishes to buy the Assets (defined below);

     WHEREAS, Seller and Buyer desire to provide for other arrangements ancillary to the purchase
and sale of the Assets; and

     WHEREAS, concurrently with the execution of this Agreement, Buyer’s parent, Pharmexa A/S has
executed and delivered in favor of Seller the Guaranty.

     NOW, THEREFORE, in consideration of the premises set forth above, which are incorporated in
this Agreement as if fully set forth below, and mutual and dependent promises set forth herein, the
parties hereto agree as follows:

ARTICLE 1 CERTAIN DEFINITIONS.

The following defined terms shall have the following meanings:

     1.1 “Affiliate” means, with respect to Seller or Buyer, another corporation, limited
liability company, partnership, joint venture, other entity of any type or individual that directly
or indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with Seller or Buyer, respectively.

     1.2 “Agreement” means this agreement and the Schedules hereto, as the same may be
extended, modified, supplemented or terminated from time to time.

     1.3 “Antigen” means any substance, including, without limitation, proteins, toxins,
viruses or bacteria, or portions of any thereof, that is capable of stimulating the production of
an immune response.

     1.4 “Assets” means all of the rights, properties and assets of Seller described in
Section 2.1 and the Schedules referenced therein.

     1.5 “Assumed Contracts” mean all contracts, agreements, licenses, and grants that
pertain to the Business, other than the Excluded Contracts.

     1.6 “Assumed Liabilities” mean (i) all obligations, duties and liabilities of Seller
under the Assumed Contracts continuing after the Closing Date which become due and payable or are
required to be performed after the Closing Date, provided that Buyer is not assuming any
liabilities under the Assumed Contracts for services, goods or any other benefit provided to Seller
prior to the Closing Date for which payment becomes due after the Closing Date

- 1 -

 

(including, but not limited to obligations to pay third party service providers under the NIH
Grants for amounts Buyer receives as reimbursement for pass through expenses from the government);
(ii) all liabilities to extent arising out of or relating to use or ownership of the Assets or the
conduct of the Business but only to the extent they arise after the Closing; (iii) all liabilities
for taxes arising out or relating to the use, ownership, sale or lease of any of the Assets after
the Closing, including all liabilities in respect of products of the Business sold/and or services
of the Business performed by Buyer or its affiliates after Closing,
and (iv) all liability for [. . . *** . . .] owed by Seller to the Hired Employees as of the Closing.

     1.7 “Business” means the Facility, the laboratories at the Facility used for
immuno-monitoring and peptide binding research and experimentation, including without limitation a
vivarium, the Equipment, EIS, the Padre Technology and the research, development, manufacture and
sale of pharmaceutical compounds and products for the treatment and prevention of diseases,
excluding the research, development, manufacture and sale of pharmaceutical compounds and products
for the treatment and prevention of cancer as conducted by Seller on or prior to the date of this
Agreement and any Excluded Assets and excluding any of the activities of Seller relating to its
corporate or financial operations as a reporting company under the Securities Exchange Act of 1934
or as a company listed for trading on the Nasdaq National Market.

     1.8 “Closing” or “Closing Date” shall have the meaning set forth in Section
8.1.

     1.9 “Closing Payment” shall have the meaning set forth in Section 6.4.

     1.10 “Hired Employees” means those employees of Seller identified on Schedule
1.10 who accept employment with Buyer.

     1.11 “Employee Benefit Plan” shall have the meaning set forth in Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended.

     1.12 “Environmental Laws” means any applicable laws relating to or imposing liability
or standards of conduct concerning hazardous or toxic materials and substance, air pollution
(including noise and odors), water pollution, liquid and solid waste, pesticide, drinking water,
community and employee health, environmental land use management, stormwater, sediment control,
radiation, wetlands, endangered species, environmental permitting and petroleum products, in effect
as of the Closing Date, including but not limited to those dealing with public health and safety
and the protection of the environment, such as the Federal Insecticide, Fungicide, and Rodenticide
Act, 7 U.S.C. 136 et seq., as amended; the Toxic Substances Control Act, 15 U.S.C.
2601 et seq., as amended; the Clean Water Act, 33 U.S.C. 1251 et
seq., as amended; the National Environmental Policy Act, 42 U.S.C. 4321 et
seq., as amended; the Solid Waste Disposal Act, 42 U.S.C. 6901 et seq., as
amended; the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. 9601
et seq., as amended; the Clean Air Act, 42 U.S.C. 7401 et seq., as
amended; the Emergency Planning and Community Right-to-Know Act, 42 U.S.C. 11001 et
seq., as amended; the Resource Conservation and Recovery Act, as amended, all applicable
state, county and municipal laws and ordinances relating to environmental, health and safety
matters; and all rules and regulations promulgated pursuant to such federal, state, county and
municipal laws and ordinances.

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 2 -

 

     1.13 “Epitope” means a molecular region of an Antigen, which is involved in
recognition by a particular immunoglobulin, or in the context of T cells, by a T cell receptor
and/or Major Histocompatibility Complex (MHC) receptor.

     1.14 “Epitope Identification System” or “EIS” means proprietary methods of
using sequence information derived from an Antigen to identify and/or characterize Antigen-specific
Epitopes, to design vaccines, to identify Epitope analogues, to identify optimal Epitope variants,
and to design Epitope minigene constructs, which methods are claimed or disclosed in the Patents
listed on Schedule 1.27(ii) and any abandoned parent applications of any Patents listed
therein as of the Closing Date.

     1.15 “Equipment” means the machinery, computers, office equipment, laboratory
equipment, supplies and office furniture located at the Facility and the leasehold improvements of
Seller associated with the Facility, but excluding personal computers or other Equipment owned by
Seller’s employees and excluding the Equipment set forth on Schedule 1.15.

     1.16 “Excluded Assets” means (a) cash and cash equivalents, (b) investments, (c)
accounts receivable, including billed and unbilled receivables for work or projects performed by
Seller under Assumed Contracts prior to Closing, including all rights to be reimbursed under
Assumed Contracts for pass-through expenses incurred and paid by Seller whether the invoice for the
pass-through expense is received before or after the Closing, (d) pre-paid expenses, (e) assets of
Seller’s Employee Benefit Plans, (f) all rights relating to Seller’s research, pre-clinical and
clinical programs targeting cancer, including EP-2101 and its investigational new drug application,
for EP-2101 filed with the Food and Drug Administration and other books and records relating
thereto, provided that the right to use PADRE universal helper T cell Epitope in Seller’s cancer
vaccines will be licensed back to Seller pursuant to the License Agreement referenced in Section
1.45(d), (g) the Patents and other Intellectual Property in the excluded vaccine programs
referenced in clause (f) above, (h) clinical supplies of EP-2101, including raw materials, the
active and other ingredients and packaging and related documentation, (i) contracts relating solely
to the excluded vaccine programs referenced in clause (f) above, including the [. . . *** . . .],
(j) ImmunoStealth Epitope modification technologies, including Patents and other Intellectual
Property that relate exclusively to such technologies, (k) all rights under Seller’s insurance
policies, (l) all claims and counterclaims with respect to rights of offset against Excluded
Liabilities, (m) the Excluded Contracts, (n) Permits relating to the Business that are not
transferable, (o) personnel files for Hired Employees, and (p) all minute books, stock books,
option and employee stock ownership plan documents and plan administration records, general ledger,
work papers and other accounting records, records maintained for compliance with United States
securities laws or the listing agreement or requirements for the Nasdaq National Market, tax
returns, Employee Benefit Plan records and similar corporate records of Seller.

     1.17 “Excluded Contracts” mean confidentiality agreements, material transfer
agreements, licenses and research agreements that do not relate exclusively to the Business and
Vendor Accounts.

	1.18	 	“Excluded Liabilities” has the meaning set forth in Section 9.1(a).

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 3 -

 

     1.19 “Existing Library” means the database comprising the library of Epitopes existing
as of the Closing Date, which Epitopes are claimed or disclosed in the Patents identified on
Schedule 1.27(ii) and any abandoned parent applications of any Patents listed therein.

     1.20 “Facility” means Seller’s facility located at 5820 Nancy Ridge Drive, Suite 100,
San Diego, California.

     1.21 “Governmental Authority” means any court, tribunal, arbitrator, authority,
agency, commission, department, organization, official or other legislative, executive, judicial or
quasi-governmental instrumentality of any foreign jurisdiction, the United States or any state,
county, city or other political subdivision.

     1.22 “Hazardous Material” means any pollutant, contaminant, hazardous, toxic or
dangerous waste, substance or material, including, but not limited to, any chemical products,
petroleum substances, PCBs, asbestos, urea formaldehyde, ammonia, nitrates, semi-volatile or
purgeable organics, flammable explosives, radioactive materials, hazardous waste, metals or other
materials or substances defined as or included in the definition of substances defined as
“hazardous substances,” “hazardous materials,” “hazardous waste,” “solid waste,” “toxic substances”
or analogous definitions under any Environmental Law.

     1.23 “Indemnification Notice” shall have the meaning set forth in Section 9.3(a).

     1.24 “Indemnitee” shall have the meaning set forth in Section 9.3(a).

     1.25 “Indemnitor” shall have the meaning set forth in Section 9.3(a).

     1.26 “Intellectual Property” means Patents, Know-How, and the goodwill associated with
all the foregoing.

     1.27 “Intellectual Property Assets” mean (i) the PADRE Technology (ii) the Patents
comprising EIS as listed on Schedule 1.27(ii), and related Know-How; (iii) the trademarks
“PADRE”, “EPIMMUNE” (typed drawing), “EPIMMUNE” (design plus word), and “EIS”; (iv) the Patents
used in Seller’s existing research, pre-clinical and clinical programs targeting hepatitis B virus
(HBV), hepatitis C virus (HCV) and human papilloma virus (HPV), as listed on Schedule
1.27(iv), and related Know-How, subject to all third party rights in such programs and
Intellectual Property; (v) the Patents used in Seller’s existing research, pre-clinical and
clinical programs targeting human immunodeficiency virus (HIV): EP HIV-1090, EP-1043, EP-1233 and
MVA mBN32, as listed on Schedule 1.27(iv), and related Know-How, subject to all third party
rights in such programs and Intellectual Property; (vi) the Patents used in Seller’s existing
programs targeting malaria, influenza, cytomegalovirus (CMV) and tuberculosis, as listed on
Schedule 1.27(iv), and related Know-How; and (vii) subject to the provisions of Section
3.14 of this Agreement, the domain name www.epimmune.com.

     1.28 “Inventory” means the laboratory and other supplies located at the Facility,
including the animals in the vivarium and excluding the assets on Schedule 1.28.

- 4 -

 

     1.29 “Know-How” means methods, procedures, trade secrets, formulas, techniques,
assays, protocols, procedures, processes, systems, specifications, data, results of clinical
trials, and technical data.

     1.30 “Legal Requirement” means any federal, state, local, municipal, foreign or other
law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree,
rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or
otherwise put into effect by or under the authority of any Governmental Authority.

     1.31 “Lien” means any lien, charge, encumbrance, claim, pledge, security interest or
grant of right, title or interest in an asset to any party.

     1.32 “Material Contracts” mean any Assumed Contract having (i) a term of greater than
[. . *** . ] (excluding any renewal option other than those that may be exclusively
exercised by the other party thereto) and (ii) a financial obligation in excess of [. . . *** . . .],
but excluding material transfer agreements, confidentiality agreements and non-disclosure
agreements.

     1.33 “Materials” means the compounds and other materials used or for use exclusively
in the Programs, which compounds and other materials constitute all of the compounds and other
materials located at the Facility as of the Closing Date.

     1.34 “NIH Grants” mean (i) NIH Award No. N01-A1-25480 (Millennium Vaccine Initiative –
Novel Vaccine for Tuberculosis and Malaria) (ii) NIH Award No. N01-A1-30031 (HIV Vaccine Design and
Development Teams), in each case as amended and (iii) Grant Number 5 P01 AI48238 (Epitope Based DNA
Vaccines for AIDS Therapy) which terminated in June 2005.

     1.35 “Notice Date” has the meaning set forth in Section 9.3(a).

     1.36 “PADRE Technology” means the Patents listed on Schedule 1.36 and related
Know-How.

     1.37 “Patents” means United States and foreign patents and patent applications,
including, without limitation, certificates of invention and applications for certifications of
invention, registered designs and registered design applications, industrial designs and industrial
design applications and registrations, reissues, extensions, substitutions, confirmations,
registrations, revalidations, renewals, term restorations, additions, provisionals, continuations,
continuations-in-part and divisions thereof.

     1.38 “Permits” mean all permits, licenses, approvals, and other authorizations in each
case granted or issued by any Governmental Authority.

     1.39 “Permitted Liens” mean (a) Liens for taxes and other governmental charges that
are not yet due and payable or that may hereafter be paid without penalty, (b) the rights, if any,
of third-party suppliers or other vendors having possession of Equipment created by virtue of
applicable laws pertaining to the possession of assets in general, (c) Liens which do not
materially impair the current use or the value of the Assets subject to such Liens either
individually or taken as a whole, (d) the terms and conditions of all licenses of in-licensed

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 5 -

 

Intellectual Property Assets set forth on Schedule 1.27, the terms of any material
transfer agreements and non-disclosure or confidentiality agreements relating to the Assets and the
terms and conditions of all licenses to commercially available software included in the Assets, (e)
all licenses of PADRE Technology, EIS or other Intellectual Property Assets granted by Seller prior
to the date of this Agreement set forth on Schedule 1.27 and all material transfer
agreements and non-disclosure or confidentiality agreements granted by Seller prior to the date of
this Agreement, and (f) those Liens described in Schedule 1.39.

     1.40 “Person” means any individual, corporation, partnership, limited liability
company, private or public institution, group, tribunal, government authority or other entity.

     1.41 “Programs” mean the programs identified in clauses (iv), (v) and (vi) of Section
1.26.

     1.42 “Purchase Price” means the amount to be paid by Buyer to Seller for the Assets as
set forth in Section 2.4.

     1.43 “Representative” means, with respect to either party, any Person that is or
becomes (i) a subsidiary or other Affiliate of the party or (ii) an officer, director, manager,
employee, partner, attorney, advisor, accountant, agent or representative of such party of such
party’s subsidiaries

     1.44 “Sales Tax” shall have the meaning set forth in Section 3.6.

     1.45 “Transaction Agreements” mean:

          (a) such deeds and instruments of sale, conveyance, transfer and assignment as are necessary
or reasonably desirable to vest in Buyer all of the Assets free and clear of all liens, claims and
encumbrances other than the Assumed Liabilities and Permitted Liens including but not limited to
the Bill of Sale, substantially in a form to be mutually agreed by the Parties;

          (b) the Assignment and Assumption Agreement, substantially in a form to be mutually agreed by
the Parties;

          (c) the License Agreement between Seller and Buyer pertaining to the Intellectual Property
comprising the Epitope Identification System, substantially in the form attached as Exhibit
1.45(c) (the “EIS License Agreement”);

          (d) the License Agreement between Buyer and Seller pertaining to the Intellectual Property
comprising the PADRE Technology, substantially in the form attached as Exhibit 1.45(d)
(together with the EIS License Agreement, the “License Agreements”);

          (e) the Services Agreement, substantially in the form attached as Exhibit 1.45(e) (the
“Services Agreement”);

- 6 -

 

          (f) the Novation Agreement related to the NIH Grants (other than the grant in clause (iii) of
the definition of NIH Grants), substantially in the form attached as Exhibit 1.45(f) (the
“Novation Agreement”);

          (g) assignments to all Intellectual Property Assets; and

          (h) assignment of the “Epimmune” and “PADRE” trademarks.

     1.46 “Vendor Accounts” means contracts or accounts with utility or third party service
providers to the Facility (such as San Diego Gas & Electric and SBC ) that are provided on a
purchase order or open account basis for which Buyer will have to open new accounts.

ARTICLE 2 SALE AND PURCHASE OF ASSETS.

     Subject to the terms and conditions and on the basis of and in reliance on the
representations, warranties, obligations and agreements set forth in this Agreement, the parties
agree to consummate on the Closing Date the following transactions:

     2.1 Assets to be Acquired. Seller shall sell, assign, transfer and convey and Buyer
shall purchase and accept free and clear of all Liens of any kind, whether absolute, accrued,
contingent or otherwise (except for any Assumed Liabilities and Permitted Liens) all of the
following assets (which are referred to in this Agreement as the “Assets”), other than the
Excluded Assets (For the avoidance of doubt, Buyer is not acquiring any assets of Seller associated
with its operations at any of its locations other than the Facility):

          (a) the Equipment;

          (b) the Intellectual Property Assets, Materials and Existing Library;

          (c) the Inventory;

          (d) all leasehold improvements at the Facility and intangible assets used in the Business such
as computer programs, records and data but excluding computer programs licensed to Seller as part
of any master enterprise licenses that are Excluded Assets;

          (e) all rights and interests of Seller in and under the Assumed Contracts;

          (f) all rights of recovery of any kind relating to or affecting the Assets or Assumed
Liabilities (excluding rights to recoveries under insurance policies covering the Assets which are
Excluded Assets) and claims, causes of action and rights under, pursuant to, or arising from
warranties, representations, guarantees and agreements in favor of Seller made by third parties;

          (g) all Permits related to the Facility or Business, including those set forth on Schedule
2.1(g), except those which are non-transferable;

          (h) all books and records pertaining to the Business, including but not limited to the
clinical and regulatory files for the Programs to the extent controlled by Seller and to the

- 7 -

 

extent legally transferable, laboratory notebooks, reports and other research documentation,
but excluding personnel files of Seller with respect to the Hired Employees and, for the avoidance
of doubt, excluding those books and records that relate exclusively to the research, development,
manufacture and sale of pharmaceutical compounds and products that are Excluded Assets;

          (i) the software and databases that are part of the Epitope Identification System subject to
the rights granted to Seller under the EIS License Agreement;

          (j) all right to payments under the NIH Grants for work to be performed by Buyer after the
Closing; and

          (k) all other assets located at the Facility that are used in the Business and that are not
Excluded Assets.

     2.2 Assumption of Liabilities. From and after the Closing, Buyer shall assume and
thereafter shall pay, perform and discharge, as and when due, the Assumed Liabilities.

     2.3 Obligations Not Assumed. Buyer shall not assume any debts, duties, obligations,
responsibilities or liabilities of Seller or any of its Affiliates of any kind or nature,
contingent or otherwise other than the Assumed Liabilities. In furtherance, and not in limitation
of this Section 2.3, Buyer does not assume, undertake or accept any debts, duties, obligations,
responsibilities or liabilities of Seller or any of its Affiliates which are not Assumed
Liabilities with respect to:

          (a) the conduct of the Business by Seller or any of its Affiliates prior to the Closing Date,
including but not limited to all liabilities, debts, duties, obligations, responsibilities due to
be paid or performed prior to the Closing or which pertain to goods delivered or services performed
prior to the Closing, and contingencies of any kind which arose on or prior to the Closing Date,
including but not limited to those obligations and contingencies that are not known as of the
Closing Date but which become known thereafter;

          (b) obligations with respect to the Assumed Contracts arising from or related to any default
or breach by or on behalf of Seller or any of its Affiliates;

          (c) any accounts payable of the Seller which arose prior to the Closing Date, regardless of
whether invoiced before or after the Closing Date;

          (d) any federal, state or local taxes of any nature whatsoever, or penalties or interest
arising therefrom, incurred by or arising out of Seller’s ownership, control or operation of the
Assets, the Business and the Facility on or before the Closing Date; and

          (e) obligations to any employee, stockholder, director or officer of Seller for salary,
wages, fringe benefits, vacation or severance pay or other amounts due for services performed for
Seller prior to the Closing Date or for severance payments to any employee of Seller relating to
such employee’s employment with Seller or under any Employee Benefit Plan of Seller or any
Affiliate of Seller, excluding [. . . *** . . .] for the Hired Employees, which are being assumed
by Buyer.

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 8 -

 

     2.4 Purchase Price. Payment for the Assets will consist of aggregate consideration of
Twelve Million Dollars (US$12,000,000). At the Closing, Buyer will deliver to Seller Twelve
Million Dollars (US$12,000,000) by wire transfer of immediately available funds to a bank account
to be designated in writing by Seller.

     2.5 Third Party Consents. Notwithstanding anything to the contrary in this Agreement,
this Agreement shall not constitute an agreement to transfer any Assumed Contract, or any claim,
right or benefit arising under or resulting from an Assumed Contract that has not been obtained
prior to Closing, if such transfer or attempt to make such transfer, without the consent or
approval of a third party, would constitute a breach or violation thereof or adversely affect the
rights of Seller thereunder; and no action under this Agreement shall constitute a transfer of such
an Assumed Contract in the absence of such consent or approval. To the extent that Seller is
unable to transfer any contract that would otherwise constitute an Assumed Contract, Seller and
Buyer shall use commercially reasonable efforts to enter into arrangements sufficient to provide
equivalent benefits and burdens to Buyer. The foregoing provisions of this Section 2.5 do not in
any way limit Buyer’s rights under Section 7.5. If the Novation Agreement is not effective as of
the Closing, then Seller and Buyer shall be deemed to have entered into a subcontract under the NIH
Grants pursuant to which Buyer, as subcontractor, hereby agrees to perform all of the services of
Seller under the NIH Grants in accordance with the terms of such NIH Grants for a period beginning
on the day after the Closing Date and ending on the effective date of the Novation Agreement.
Seller shall pay Buyer under the subcontract all amounts that are payable to Seller under the NIH
Grants for the subcontract period as if the Novation Agreement were effective at the beginning of
the subcontract period.

ARTICLE 3 CERTAIN COVENANTS OF THE PARTIES.

     3.1 Tax Allocation. The cash portion of the Purchase Price plus the Assumed
Liabilities will be allocated among the Assets for tax purposes as set forth in Schedule
3.1. The parties shall revise the allocation schedules from time to time as mutually agreed to
take into account any purchase price adjustment. All tax filings made by the parties shall be
consistent with the agreed upon allocation of the Purchase Price.

     3.2 Business in the Ordinary Course. Except as may be necessary to facilitate
compliance with any Legal Requirement or the requirements of any Assumed Contract or as approved by
Buyer in writing, between the date of this Agreement and the earlier of (i) the Closing Date and
(ii) the termination of this Agreement:

          (a) Other than in the ordinary course of business, Seller shall not engage in any transactions
involving the Assets and the Business and shall not subject the Assets to any Lien other than
Permitted Liens;

          (b) Seller will promptly notify Buyer of any Lien affecting the Assets, including a Permitted
Lien of which Seller becomes aware, and will use commercially reasonable efforts to have any Liens
imposed by third parties without Seller’s knowledge or consent removed.

- 9 -

 

          (c) Seller will not conduct any activities at the Facility other than the operation of the
Business in the ordinary course in substantially the same manner as conducted by Seller on the date
hereof, and the operation of Seller’s other business not being sold to Buyer hereunder;

          (d) Seller shall, consistent with past practice, maintain the physical Assets in good
operating condition, reasonable wear and tear excepted;

          (e) Seller shall, consistent with past practice, maintain in full force and effect the Assumed
Contracts (subject to any scheduled expiration or termination of an Assumed Contract) and all
Intellectual Property Assets (subject to the abandonment of particular claims included in pending
applications or portions of pending applications made in the ordinary course of business, and
provided that Seller will notify Buyer of the abandonment of any claims or portions of a pending
application that could reasonably be considered to be material to the Business) and Permits
included in the Assets;

          (f) Seller shall conduct the Business in material compliance with all laws, ordinances, rules,
regulations and judicial and administrative orders applicable to the operation of the Business; and

          (g) Seller shall promptly advise Buyer in writing of all lawsuits, claims, proceedings and
investigations of which Seller, to its best knowledge, becomes aware, that may be threatened,
brought, asserted or commenced against Seller involving (a) the consummation of the transactions
contemplated by this Agreement or (b) which might have a material adverse effect on the Business.

     3.3 Third Party Consents. To the extent that Seller’s rights under any of the Assumed
Contracts are not assignable without the consent of any Person not a party hereto, Seller will use
commercially reasonable efforts to obtain such consent prior to the Closing. Buyer and Seller
shall use commercially reasonable efforts prior to and after the Closing to obtain the U.S.
government’s approval of the Novation Agreement, and promptly following the date of this Agreement,
Buyer will contact the contracting officer or other governmental authority with jurisdiction over
the novation of the NIH Grants (other than the grant in (iii) of the definition of NIH Grants,
which shall not be novated) and take appropriate actions to initiate novation of such NIH Grants in
accordance with 48 C.F.R. Chapter 1, Subparts 42.1203 and 42.1204 (Federal Acquisition Regulation).

     3.4 Post-Closing Assistance.

          (a) At Buyer’s request, Seller will make available Persons that remain employees of Seller
after the Closing for the purpose of giving testimony or such other assistance as Buyer may
reasonably require for the preparation and defense or prosecution of any claim, action or other
proceeding against any third party relating to the Assets or the Assumed Liabilities. Seller’s
reasonable costs and expenses in connection therewith shall be reimbursed by Buyer, including but
not limited to, reimbursement of Seller and its Affiliates for the time of their employees at a
rate to be mutually agreed upon.

- 10 -

 

          (b) With respect to the Excluded Contracts (including but not limited to all confidentiality
agreements and other agreements that include a provision regarding the protection and restriction
on the use of proprietary and confidential information), in the event of a breach by the other
party to any such contract which adversely affects the Business in any material respect, Seller
will cooperate with Buyer and take such actions as Buyer may reasonably request, at Buyer’s
expense, to enforce the Excluded Contract.

          (c) The obligations of Seller under this Section 3.4 shall survive the Closing.

     3.5 Consummation of Transactions. Each party shall use its commercially reasonable
efforts to perform or comply with, and to cause others to perform or comply with, all of the terms
and conditions set forth in this Agreement, including but not limited to the fulfillment of the
conditions precedent to the obligation of the other party to close the transactions contemplated
herein. Neither party will take any action that it is aware would result in a material breach by
such party of any of its representations and warranties under this Agreement.

     3.6 Cooperation. Buyer and Seller shall cooperate with each other and proceed, as
promptly as is reasonably practicable, to prepare and file the notifications and other filings
required by applicable law in connection with the transactions described in this Agreement and to
comply with all other legal and contractual requirements necessary to consummate the Closing.

     3.7 Taxes. Any transfer tax (such as a sales tax) imposed due to the transfer and
sale of the Assets to Buyer will be borne by Buyer. At the Closing, Buyer shall pay Seller for the
sales tax due as a result of the sale of the Assets to the Buyer (the “Sales Tax”). Buyer
shall pay all other transfer, documentary, sales, use, stamp, registration and other such taxes and
fees (including any penalties and interest) incurred in connection with this Agreement, when due,
and Buyer shall, at its own expense, file all necessary tax returns and other documentation with
respect to all such transfer, documentary, sales, use, stamp, registration and other taxes and fees
(except with respect to the Sales Tax). To the extent that any sales and use taxes that may be
levied or imposed by any state, county, city or other political subdivision in respect of any sales
made by Seller prior to the Closing have not been fully paid, satisfied, and discharged by Seller
at or prior to the Closing, then Seller will pay, satisfy and discharge the same following the
Closing as required by applicable law.

     3.8 Receipt of Monies or Other Assets. If any monies or other assets are received by
Seller or Buyer after Closing to which the other party is entitled in accordance with the terms of
this Agreement, such party shall promptly forward such monies or other assets to the other party
within [. . . *** . . .] of receipt.

     3.9 Payment of Rents and Utilities. Seller will be responsible for and pay when due
all rents and utility and other Vendor Account costs associated with the Facility through the
Closing Date. Utility or other Vendor Account bills and rent prepaid by Seller prior to Closing
which cover services to be provided to Buyer after Closing will be proportionately allocated
(except that any security deposit and all prepaid rent that is required to be maintained for the
duration of the lease shall be allocated solely to Buyer) between Seller and Buyer for the period
covered, and Buyer will reimburse Seller at Closing for any such amount paid by Seller that is

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 11 -

 

allocated to Buyer. Utility and other Vendor Account bills and rent paid by Buyer after
Closing which cover services provided to Seller prior to Closing shall also be proportionately
allocated between Seller and Buyer for the period covered, and, upon Buyer’s request, Seller will
promptly reimburse Buyer for any such amount paid by Buyer that is allocated to Seller. Buyer
shall arrange with each vendor of any Vendor Account to open a new account in its name following
the Closing or will replace or discontinue such service but Seller shall not remain a party to any
Vendor Account relating to the Facility.

     3.10 Facility Lease. With regard to the Lease between Seller and ARE-SD Region No.
18, LLC, as the successor to Nexus Equity VIII LLC, (the “Landlord”) dated November 1, 1998
(the “Lease”), which is being assumed by Buyer, Buyer shall (i) obtain a substitute letter
of credit to replace the letter of credit that Seller has in place with the Landlord and (ii) use
reasonable efforts to obtain from the Landlord a release of Seller for all obligations under the
Lease arising on and after the Closing.

     3.11 Employee Matters. Excluding the Hired Employees, Buyer shall have no liability
whatsoever with respect to any matter pertaining to the employment by Seller of any employee prior
to the Closing Date, including but not limited to any obligations under any of Seller’s Employee
Benefit Plans. With respect to the Hired Employees, Buyer agrees to assume Seller’s obligation for
[. . . *** . . .] that are included in the Assumed Liabilities, but not any other obligation of
Seller to the Hired Employees, including but not limited to any obligations under any of Seller’s
Employee Benefit Plans.

     3.12 Allocations Under NIH Grants. Seller shall be responsible and pay when due all
third party costs that are reimbursable as pass-through expense under the NIH Grants through the
Closing Date, even if invoices for such third party costs are received after the Closing Date.
Third party costs that are prepaid by Seller prior to Closing which cover services to be provided
to Buyer after Closing will be proportionately allocated between Seller and Buyer for the period
covered, and Buyer will reimburse Seller at Closing for any such amount paid by Seller that is
allocated to Buyer. Third party costs which cover both services provided to Seller prior to the
Closing and services to be provided to Buyer after the Closing that are invoiced after the Closing
shall be paid by Buyer and shall be proportionately allocated between Seller and Buyer for the
period covered. Seller will reimburse Buyer within [. . . *** . . .] after receipt of an invoice
therefor. Buyer shall provide to Seller such information and documentation as is required for
Seller to be able to bill the National Institute of Health or other third party for the
pass-through of such third party costs incurred by Seller on or prior to the Closing Date and any
other information required for Seller to bill for work or projects performed by Seller under the
NIH Grants on or prior to the Closing Date.

     3.13 Update Schedules. Between the date of this Agreement and the earlier of (i) the
Closing Date or (ii) the termination of this Agreement, each party shall promptly notify the other
in writing of any material breach or inaccuracy of any representation made by it in this Agreement
and will supplement or amend the Schedules delivered by it hereunder with respect to any matter
which hereafter becomes known to it. At the Closing, for informational purposes only and not as a
representation and warranty or a condition to Closing, Seller will deliver to Buyer an update of
Schedule 4.5(c) to a date as proximate to the Closing as reasonably feasible for
calculating the information in Schedule 4.5(c).

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 12 -

 

     3.14
Domain Name. Seller shall not transfer the domain name, www.epimmune.com, to
Buyer until the date that is six months following the Closing Date (the “Transfer Date”),
and Buyer shall not use or refer to this domain name in any of its materials until after the
Transfer Date so that Seller can continue to route e-mail and other communications received through
this domain address to Seller’s other accounts and Seller shall have no obligation to route e-mail
or other communications to Buyer prior to the Transfer Date. After the Transfer Date, Seller shall
not use or refer to this domain name in any of its materials and Buyer shall have no obligation to
route e-mail or other communications received through this domain address to Seller.

ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF SELLER.

     As an inducement to Buyer to enter into this Agreement and to consummate the transactions
contemplated hereby, Seller hereby represents and warrants to Buyer that:

     4.1 Organization and Good Standing. Seller is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and is duly qualified to
conduct business and is in good standing in each of the jurisdictions in which it conducts business
where the failure to so qualify would have a material adverse effect on the Business or the Assets.

     4.2 Compliance with Law.

          (a) During the year prior to this Agreement, Seller’s use of the Assets, its operation of the
Business, its occupancy and operation of the Facility are in compliance in all material respects
with all applicable laws, orders, rules, regulations or ordinances to which Seller is subject.
Seller’s execution, delivery and performance of this Agreement and the Transaction Agreements do
not violate any applicable law, order, rule, regulation or ordinance to which Seller is subject.

          (b) Except as set forth on Schedule 4.2(b), no consent, order, license, certificate,
permit and/or authorization of any Governmental Authority is required to be obtained by Seller in
order to permit it to execute and deliver and consummate and perform the transactions contemplated
by this Agreement and the Transaction Agreements.

     4.3 Authority and Compliance.

          (a) Seller has full corporate power and authority to execute and deliver this Agreement and
the Transaction Agreements and to perform the transactions contemplated hereby and thereby. The
execution, delivery and performance by Seller of this Agreement and the Transaction Agreements have
been duly authorized and approved by all requisite corporate action on the part of Seller. This
Agreement constitutes (and, upon execution and delivery at the Closing, each of the Transaction
Agreements will constitute) a legal, valid and binding obligation of Seller and is and will be
enforceable against Seller in accordance with its terms, except as such enforceability may be
limited by principles of public policy and subject to the laws of general application relating to
bankruptcy, insolvency and the relief of debtors and the rules of law governing specific
performance, injunctive relief or other equitable remedies.

- 13 -

 

          (b) The execution and delivery by Seller of this Agreement and the Transaction Agreements and
the consummation and performance by Seller of the transactions contemplated hereby and thereby will
not: (i) violate the Certificate of Incorporation or By-Laws of Seller; (ii) conflict with or
result in a breach of any of the terms, conditions or provisions of, or constitute a default under,
any Assumed Contract or any other agreement that would give rise to a claim against Buyer or give
rise to a claim by any third party of any rights in or to any of the Assets; or (iii) give any
third party the right to terminate, modify or otherwise change the rights or obligations of Seller
under any Assumed Contract.

          (c) Seller has not violated any applicable statute, order, rule or regulation, which violation
would prevent the consummation of the transactions contemplated in this Agreement or any of the
Transaction Agreements.

     4.4 Assets.

          (a) Seller is the sole and exclusive owner of the Assets and has title to all of the Assets
free and clear of any Lien, except for any Assumed Liabilities and Permitted Liens. Upon transfer
and conveyance to Buyer of the Assets, Buyer shall receive title to the Assets free and clear of
all Liens, except for any Assumed Liabilities and Permitted Liens.

          (b) The Assets include substantially all of the assets used in the operation of the Business
as it had been conducted by Epimmune, Inc. immediately prior to the consummation of the
Combination, less (i) assets that exclusively pertain to the prevention and treatment of cancer,
(ii) Equipment and Inventory consumed or depleted in the ordinary course of business, (iii)
services performed by Seller under the NIH Grants or other Assumed Contracts prior to the Closing
and (iv) the Excluded Assets. For the purposes of this Agreement, the “Combination” means
the business combination between Epimmune, Inc. and Immuno-Designed Molecules, S.A.

     4.5 Assumed Contracts.

          (a) Schedule 4.5(a) lists all of the Material Contracts.

          (b) All of the Assumed Contracts are in full force and effect, and, to Seller’s knowledge, are
legal, valid and binding obligations of the other parties thereto, enforceable against such parties
in accordance with their terms, except as such enforceability may be limited by principles of
public policy and subject to the laws of general application relating to bankruptcy, insolvency and
the relief of debtors and the rules of law governing specific performance, injunctive relief or
other equitable remedies. Seller is not now in default in the performance of any material term of
any of the Assumed Contracts, and no event has occurred which, with notice or lapse of time or
both, would constitute a default by Seller under any such contract. Seller has not received any
notice of cancellation or termination of any of the Assumed Contracts. To Seller’s knowledge, none
of the other parties to the Assumed Contracts have committed a breach thereunder. All of the
Material Contracts may be assigned by Seller to Buyer without obtaining the consent of the other
party to the contract, except for those Material Contracts identified as requiring such consent on
Schedule 4.5(a).

- 14 -

 

          (c) Schedule 4.5(c) sets forth as of October 31, 2005 the remaining authorized funding
available under each of the NIH Grants taking into account Seller’s billed and unbilled NIH
receivables.

          (d) The aggregate remaining financial obligation of Seller for payments under Assumed
Contracts that are not Material Contracts or listed on Schedule 4.5(a) would not exceed
[. . . *** . . .] if all of those contracts were terminated by Seller immediately prior to Closing.

     4.6 Intellectual Property Assets.

          (a) Schedule 4.6(a) contains a complete list of the registered Intellectual Property
Assets. Seller has taken all measures it deems reasonably necessary and appropriate to obtain
patent or other protection for the Intellectual Property Assets. There are no legal actions or
investigations, inquiries or proceedings of any state or federal government agency pending or, to
Seller’s knowledge, threatened that question the validity, scope, ownership or inventorship or use
of the Patents or trademarks included in the Assets or use of the Know-How included in the Assets.
Seller is not subject to any outstanding order, judgment or decree of any court or administrative
agency and has not entered into any stipulation or, except as set forth on Schedule 4.6(a),
any agreement that would prevent Buyer’s use of the Intellectual Property Assets in any field or in
general. Seller has not licensed to any party the right to use any of the Intellectual Property
Assets and no third parties have been granted or are entitled to any rights in or to the Programs
or other Intellectual Property Assets except for those licenses and rights granted pursuant to the
Material Contracts listed on Schedule 4.6(a) and rights granted under material transfer
agreements and non-disclosure or confidentiality agreements.

          (b) Seller has not received any claim or otherwise become aware that its use of any of the
Assets infringes the Intellectual Property rights of any other Person.

          (c) There are no royalties, milestone payments, license fees or other payments that are
currently payable by Seller or that will be payable by Seller as of the Closing Date under any of
the in-licenses included in the Material Contracts (including but not limited to any such payments
that as of the Closing Date will have been earned by the other party thereto but are not payable
until after the Closing Date).

     4.7 Equipment. The Equipment is in good condition for assets of that age and type,
normal wear and tear excepted.

     4.8 Legal Proceedings. There are no claims or actions pending or, to Seller’s best
knowledge, threatened, against Seller or any of its Affiliates before any court, governmental
authority, or arbitrator pertaining to the Business or involving the Assets which would have a
material adverse effect upon the Business or the Assets. Seller and its Affiliates are not subject
to or in default with respect to any indictment, order, injunction, decree or award of any court,
arbitrator or governmental agency directly relating to the Business or the Assets, or which would
adversely affect the ability of Seller to execute, deliver and carry out its obligations under this
Agreement and the Transaction Agreements. There are no claims or actions pending, or, to Seller’s
best knowledge, threatened against Seller before any court, governmental authority, or arbitrator,
which question or challenge the validity of this Agreement or any of the Transaction

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 15 -

 

Agreements or any action taken, or to be taken, by Seller pursuant to this Agreement or any of
the Transaction Agreements, or in connection with the transactions contemplated hereby or thereby,
which would have an adverse effect upon the ability of Seller to carry out its obligations under
this Agreement or any of the Transaction Agreements.

     4.9 No Finder. Seller has not paid or become obligated to pay any fee or commission
to any broker, finder or intermediary for or on account of the transactions provided for in this
Agreement.

     4.10 Permits. Seller has all material Permits that are necessary to conduct the
Business as currently conducted by Seller, including but not limited to, material Permits required
by Seller to conduct its operations at the Facility. All such Permits have been obtained by Seller
and are valid and subsisting and in full force and effect in accordance with their terms.

     4.11 Absence of Certain Events. Except as set forth on Schedule 4.11, since
September 30, 2005, Seller has not, other than in the ordinary course of business consistent with
past practices, as it relates to the Business and the Assets:

          (a) incurred or discharged any liabilities;

          (b) transferred any of the Assets;

          (c) subjected any of the Assets to any encumbrance other than a Permitted Lien;

          (d) made or suffered any amendment or termination of any Assumed Contract, or waived any
debts, claims or rights under any Assumed Contract;

          (e) suffered any damage, destruction or casualty loss;

          (f) suffered any material adverse change in its relations with any licensor, licensee or
Person that is the source of any grant;

          (g) suffered any material labor trouble involving any union or other group of employees;

          (h) made any capital expenditure or capital addition or betterment (including any capitalized
lease transaction) in excess of [. . . *** . . .] (in the aggregate); or

          (i) entered into any agreement or made any commitment to take any of the types of action
described in subparagraphs (a) through (h) above.

     4.12 Delivery of Documents. Seller has made available to Buyer true, correct and
complete copies of all documents, including all amendments, supplements or modifications thereof,
or waivers currently in effect thereunder, described or listed in the Schedules.

     4.13 Environmental Representations.

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 16 -

 

          (a) Seller is conducting the operation of the Business in compliance with all applicable
Environmental Laws and directives of federal, state and local authorities, including, without
limitation, the preparation and maintenance of records.

          (b) To Seller’s knowledge, there is no condition at the Facility which is reasonably likely to
cause the imposition of a Lien on the Assets or assessment of penalties against Buyer, or which is
reasonably likely to require remediation under any Environmental Laws, the cost of which, or the
responsibility for which, is reasonably likely to be imposed on Buyer.

          (c) To Seller’s knowledge, without conducting any investigation, there has been no spill,
discharge, burial, release, seepage or infiltration of any Hazardous Material at, on or from the
Facility in amounts which exceed reportable thresholds under applicable Environmental Laws.

          (d) The execution and delivery of this Agreement and the consummation of the transactions
contemplated herein do not require that any filing or disclosure be made by Seller under any
Environmental Laws.

     4.14 Employment Matters.

          (a) To Seller’s knowledge, none of the Hired Employees has any pending grievance, complaint or
other claim against Seller related to their employment.

          (b) Seller is in compliance in all material respects with its Employee Benefit Plans in
respect to Hired Employees.

     4.15 Program Results. Subject to any confidentiality obligations of Seller, Seller
has made available to Buyer its files of its pre-clinical and clinical trial data for the Programs
for which Seller has conducted such pre-clinical and clinical trials. Buyer acknowledges that
Seller does not have the right to receive clinical trial data for the trials being conducted by
Innogenetics or any trials being conducted of drug candidates developed by third parties using the
PADRE Technology.

     4.16 Disclosure. The representations and warranties set forth in this Article 4 do
not contain any untrue statements of a material fact or omit to state any material fact, which
omission renders the statements and information set forth in this Article 4 materially misleading.

     4.17 Taxes. Each tax, the liability for which arose prior to the Closing, related to
the Business or the Assets required to have been paid, or claimed by any Governmental Authority to
be payable, by Seller has been or will be duly paid in full by Seller on a timely basis.

ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF BUYER.

     As an inducement to Seller to enter into this Agreement and to consummate the transactions
contemplated hereby, Buyer hereby represents and warrants to the Seller that:

- 17 -

 

     5.1 Organization and Good Standing. Buyer is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and is duly qualified to
conduct business and is in good standing in each of the jurisdictions in which it conducts business
where the failure to so qualify would have a material adverse effect on Buyer’s ability to perform
its obligations under this Agreement and the other Transaction Agreements.

     5.2 Compliance with Law.

          (a) Buyer’s execution, delivery and performance of this Agreement and the Transaction
Agreements do not violate any applicable law, order, rule, regulation or ordinance to which Buyer
is subject.

          (b) No consent, order, license, certificate, permit or authorization of any Governmental
Authority is required to be obtained by Buyer in order to permit it to execute, deliver, consummate
and perform the transactions contemplated by this Agreement and the Transaction Agreements, other
than Permits Buyer will be required to obtain to conduct operations at the Facility in connection
with the services to be provided under the Services Agreement.

     5.3 Authority and Compliance.

          (a) Buyer has full corporate power and authority to execute and deliver this Agreement and the
Transaction Agreements and to perform the transactions contemplated hereby and thereby. The
execution, delivery and performance by Buyer of this Agreement and the Transaction Agreements have
been duly authorized and approved by all requisite corporate action on the part of Buyer. This
Agreement constitutes (and, upon execution and delivery at or prior to the Closing, each of the
Transaction Agreements will constitute) a legal, valid and binding obligation of Buyer and will be
enforceable against Buyer in accordance with its terms, except as such enforceability may be
limited by principles of public policy and subject to the laws of general application relating to
bankruptcy, insolvency and the relief of debtors and the rules of law governing specific
performance, injunctive relief or other equitable remedies.

          (b) The execution, delivery and performance by Buyer of this Agreement and the Transaction
Agreements and the consummation and performance by Buyer of the transactions contemplated hereby
and thereby will not: (i) violate the Certificate of Incorporation or By-Laws of Buyer or (ii)
conflict with or result in a breach of any of the terms, conditions or provisions of, or constitute
a default under, any instrument, agreement, mortgage, judgment, order, award or decree that would
give rise to a claim again Seller.

          (c) Buyer has not violated any applicable statute, order, rule or regulation, which violation
would prevent the consummation of the transactions contemplated in this Agreement or any of the
Transaction Agreements.

     5.4 No Finder. Buyer has not paid or become obligated to pay any fee or commission to
any broker, finder or intermediary for or on account of the transactions provided for in this
Agreement.

- 18 -

 

     5.5 Legal Proceedings. Buyer and Parent are not subject to or in default with respect
to any indictment, order, injunction, decree or award of any court, arbitrator or governmental
agency which would adversely affect the ability of Buyer to execute, deliver and carry out its
obligations under this Agreement and the Transaction Agreements. There are no claims or actions
pending, or to Buyer’s best knowledge, threatened against Buyer before any court, governmental
authority, or arbitrator, which question or challenge the validity of this Agreement or any of the
Transaction Agreements or any action taken, or to be taken, by Buyer pursuant to this Agreement or
any of the Transaction Agreements, or in connection with the transactions contemplated hereby or
thereby, which, if decided adversely against Buyer, would have an adverse effect upon the ability
of Buyer to carry out its obligations under this Agreement or any of the Transaction Agreements.

ARTICLE 6 CONDITIONS PRECEDENT TO THE OBLIGATIONS OF SELLER.

     The obligations of Seller under this Agreement are subject to the fulfillment on or prior to
the Closing Date of each of the following conditions, unless such condition is waived in writing by
Seller:

     6.1 Representations, Warranties and Covenants. The representations and warranties
of Buyer contained in Article 5 hereof shall be true, complete and accurate in all material
respects as of the Closing Date with the same effect as though such representations and warranties
had been made on and as of the Closing Date. Buyer shall have performed and complied with all
covenants, obligations and conditions required by this Agreement to be performed or complied with
by it on or prior to the Closing.

     6.2 Legal Matters. No suit, arbitration, governmental action or other proceeding, or
injunction or final judgment relating thereto, which seeks to restrain, prohibit, question the
validity or legality of, or otherwise challenge any of the transactions contemplated by this
Agreement or any of the Transaction Agreements shall be pending or threatened to be submitted
before any court or governmental agency by any non-affiliated third party.

     6.3 Transaction Agreements. Each of the Transaction Agreements to which Buyer or
Parent is a party shall have been duly executed and delivered by Buyer and all other required
Persons other than Seller.

     6.4 Payment of Purchase Price. Buyer shall have paid to Seller the Purchase Price as
contemplated by Section 2.4, the Sales Tax and any payment required by Section 3.9 and Section 3.12
(collectively referred to herein as the “Closing Payment”).

     6.5 Closing Certificates. Buyer shall have delivered the certificates contemplated by
Sections 8.4(b) and (c).

     6.6 Consents and Approvals. All consents listed on Schedule 6.6 shall have
been received.

ARTICLE 7 CONDITIONS PRECEDENT TO THE OBLIGATIONS OF BUYER.

- 19 -

 

     The obligations of Buyer under this Agreement are subject to the satisfaction, on or prior to
the Closing Date, of all of the following conditions unless waived in writing by the Buyer:

     7.1 Representations, Warranties and Covenants. The representations and warranties of
Seller contained in this Agreement shall be true, complete and accurate in all material respects as
of the Closing Date with the same effect as though such representations and warranties had been
made on and as of the Closing Date. Seller shall have performed and complied with all covenants,
obligations and conditions required by this Agreement to be performed or complied with by it on or
prior to the Closing.

     7.2 Legal Matters. No suit, arbitration, government action or other proceeding, or
injunction or final judgment relating thereto which seeks to restrain, prohibit, question the
validity or legality of, or otherwise challenge any of the transactions contemplated by this
Agreement or any of the Transaction Agreements shall be pending or threatened to be submitted
before any court or governmental agency by any non-affiliated third party.

     7.3 Transaction Agreements. Each of the Transaction Agreements to which Seller is a
party shall have been duly executed and delivered by Seller and all other required Persons other
than Buyer.

     7.4 Closing Certificates. Seller shall have delivered the certificates contemplated
by Sections 8.3 (b) and (c).

     7.5 Consents and Approvals. All consents listed on Schedule 6.6 shall have
been received.

     7.6 No Casualty. Since the date of this Agreement, there shall have been no damage to
the Facility or the tangible Assets that has or would reasonably be expected to have a material
adverse effect on the operation of the Business as presently conducted by Seller.

     7.7 No Adverse Novation Decision. Since the date of this Agreement, Seller shall not
have received a materially adverse determination by the contracting officer or other governmental
authority with jurisdiction over the novation of the NIH Grants (other than the grant in (iii) of
the definition of NIH Grants, which shall not be novated) that the NIH Grants cannot be novated to
Buyer.

     7.8 Certain Hired Employee Matters. Provided that Buyer has offered the Hired
Employees employment with Buyer in positions at least comparable to their positions with Seller
prior to the Closing and with compensation and benefits [. . . *** . . .] to those applicable to
such employees prior to the Closing, [. . . *** . . .].

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 20 -

 

ARTICLE 8 CLOSING PROCEDURES.

     8.1 Closing Date. The Closing shall occur on December 31, 2005, or such other time as
the parties may mutually agree upon (“Closing Date”). The Closing shall take place at the
office of Cooley Godward llp at 4401 Eastgate Mall, San Diego, California 92121.

8.2 [Intentionally omitted]

     8.3 Closing Deliveries of Seller. On the Closing Date, Seller shall deliver to Buyer
the following:

          (a) All of the documents, Transaction Agreements and instruments required to be delivered by
Seller to Buyer under Article 7 of this Agreement;

          (b) A certificate of Seller signed on its behalf by an executive officer, certifying that (i)
the warranties and representations of Seller set forth in this Agreement are true and correct in
all material respects as of the Closing Date and (ii) Seller has performed and complied with all
agreements and conditions required by this Agreement to be performed and complied with by it on or
prior to the Closing Date;

          (c) A copy of resolutions duly adopted by the Board of Directors of Seller authorizing the
execution, delivery and performance of this Agreement and all of the Transaction Agreements and the
consummation of the transactions contemplated herein and therein, certified by the Secretary of
Seller as being in full force and effect as of the Closing;

          (d) Copies of all consents required under Section 7.5;

          (e) The opinion of Cooley Godward LLP, counsel for Seller, dated the Closing Date, reasonably
satisfactory in form and substance to Buyer; and

          (f) Full, actual and unimpeded possession of the tangible Assets (subject to any Permitted
Liens and rights of Seller under the Transaction Agreements).

     8.4 Closing Deliveries of Buyer. On the Closing Date, Buyer shall deliver to Seller
the following:

          (a) All of the documents, Transaction Agreements and instruments required to be delivered by
Buyer to Seller under Article 6 of this Agreement;

          (b) A certificate of Buyer signed on its behalf by an executive officer, certifying that (i)
the warranties and representations of Buyer set forth in this Agreement are true and correct in all
material respects as of the Closing Date and (ii) Buyer has performed and complied, in all material
respects, with all agreements and conditions required by this Agreement to be performed and
complied with by it prior to or on the Closing Date;

          (c) A copy of resolutions duly adopted by the Board of Directors of Buyer authorizing the
execution, delivery and performance of this Agreement and the Transaction

- 21 -

 

Agreements and the consummation of the transactions contemplated herein and therein, certified by
the Secretary of Buyer as being in full force and effect as of the Closing;

          (d) The payment of the Closing Payment; and

          (e) The opinion of Nordlicht & Hand, counsel for Buyer, dated the Closing Date, reasonably
satisfactory in form and substance to Seller.

ARTICLE 9 INDEMNIFICATION.

     9.1 Indemnification of Buyer. Subject to Sections 9.5 and 11.1, after the Closing
Date, Seller shall defend, indemnify and hold harmless Buyer, its Affiliates and their respective
directors, officers, employees, and agents from and against:

          (a) any and all claims, damages, losses and liabilities resulting from or relating to
liabilities of Seller other than the Assumed Liabilities, including but not limited to liabilities
regarding the operation of the Business and ownership of the Assets prior to the Closing Date (even
if such liabilities do not become known until after the Closing Date) (the “Excluded
Liabilities”);

          (b) any and all damages, losses and liabilities whatsoever resulting from any breach of any
representation or warranty or nonfulfillment of any covenant or agreement on the part of Seller
hereunder, under any certificate or other instrument to be furnished by Seller under this
Agreement, or under any of the Transaction Agreements; and

          (c) any and all actions, suits, claims, proceedings, investigations, audits, demands,
assessments, fines, judgments, costs and other reasonable expenses (including reasonable legal fees
and other litigation expenses) incident to any of the foregoing.

     9.2 Indemnification of Seller. Subject to Sections 9.5 and 11.1, after the Closing
Date, Buyer shall defend, indemnify and hold harmless Seller, its Affiliates, and their respective
directors, officers, employees, and agents, from and against:

          (a) any and all claims, damages, losses and liabilities resulting from or relating to the
Assumed Liabilities and the operation of the Business and ownership of the Assets on and after the
Closing Date, including any arising with respect to any product sold or service performed by Buyer
from and after the Closing Date;

          (b) any and all damages, losses and liabilities whatsoever resulting from any breach of any
representation or warranty or non-fulfillment of any covenant or agreement on the part of Buyer
hereunder, under any certificate or other instrument to be furnished by Buyer under this Agreement,
or under any of the Transaction Agreements; and

          (c) any and all actions, suits, claims, proceedings, investigations, audits, demands,
assessments, fines, judgments, costs and other reasonable expenses (including reasonable legal fees
and other litigation expenses) incident to any of the foregoing.

- 22 -

 

     9.3 Indemnification Procedures Involving Only Seller and Buyer. Claims for
indemnification in connection with this Agreement which involve only Seller and Buyer shall proceed
as follows:

          (a) Notice. A party entitled to indemnification under this Article 9 (the
“Indemnitee”) shall so notify the party having the obligation to indemnify the Indemnitee
(the “Indemnitor”) in writing, setting forth the provision of this Agreement under which
the claim is made, and in reasonable detail the grounds therefor (an “Indemnification
Notice”). The date on which such notice is sent is the “Notice Date.”

          (b) Good Faith Discussions. Within [. . . *** . . .] after the Notice Date, the
parties shall meet, either in person or by telephone, for the purpose of resolving the Indemnitee’s
claim. Both parties agree that they will meet and negotiate in good faith for this purpose. Such
discussions and negotiations shall be conducted in accordance with the provisions for dispute
resolution set forth in Section 11.7.

     9.4 Certain Procedures Regarding Indemnification of Third Party Claims. All claims
for indemnification under this Agreement arising from claims made by unaffiliated third parties
shall be made as follows:

          (a) In the event a Claim is made by a third party against an Indemnitee (a “Third Party
Claim”), the Indemnitee shall notify the Indemnitor of such claim or demand, specifying the
nature and the amount of the third party’s claim (the “Third Party Claim Notice”). The
Third Party Claim Notice must be delivered within [. . . *** . . .] after the Indemnitee becomes
aware of the Third Party Claim, provided that the failure of the Indemnitee to comply with such
requirement shall not relieve the Indemnitor of its obligations hereunder unless the Indemnitor is
materially prejudiced in the defense of the Third Party Claim due to such failure on the part of
the Indemnitee. The Indemnitor shall have the right to undertake and control the defense of any
Third Party Claim at its expense through counsel of its own choosing (subject to the Indemnitee’s
consent to such counsel, which consent may not be unreasonably withheld or delayed). The
Indemnitor must notify the Indemnitee in writing within [. . . *** . . .] after receipt of the
Third Party Claim Notice whether the Indemnitor will assume the defense of the Third Party Claim.
If the Indemnitor undertakes the defense of a Third Party Claim: (i) the Indemnitor may not settle
such action without first obtaining the written consent of the Indemnitee, which consent will not
be unreasonably withheld or delayed, except for settlements solely covering monetary matters for
which the Indemnitor acknowledges responsibility for payment; and (ii) the Indemnitor shall permit
the Indemnitee (at the Indemnitee’s sole cost and expense) to participate in such settlement or
defense through counsel chosen by the Indemnitee.

          (b) The Indemnitee agrees to preserve and provide access to all evidence in its possession or
control that may be useful in defending against a Third Party Claim and to provide reasonable
cooperation in the defense thereof or in the prosecution of any action against a third party in
connection therewith at no additional cost to the Indemnitor. The Indemnitor’s defense of any Third
Party Claim or demand shall not constitute an admission or concession of liability therefor or
otherwise operate in derogation of any rights the Indemnitor may have against the

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 23 -

 

Indemnitee or any third party. So long as the Indemnitor is reasonably contesting any such Third
Party Claim in good faith, the Indemnitee shall not pay or settle any such Third Party Claim.

          (c) If the Indemnitor does not notify the Indemnitee within [. . . *** . . .] after receipt of
the Indemnitee’s Third Party Claim Notice that it elects to undertake the defense of the Third
Party Claim, the Indemnitee shall have the right to assume the defense of the Third Party Claim
through counsel of its own choosing and contest, settle or compromise the Third Party Claim in the
exercise of its exclusive discretion at the expense of the Indemnitor, provided, however, that if
either (i) the Indemnitor and the Indemnitee jointly agree that the Indemnitee shall control the
defense of the Third Party Claim or (ii) the Indemnitor claims that it is not required to indemnify
the Indemnitee for the Third Party Claim and has a reasonable basis for such claim, then in either
such case no Indemnitee may consent to the entry of any judgment or enter into any settlement of
any Third Party Claim without the prior written consent of the Indemnitor, which consent shall not
be unreasonably withheld or delayed. All documented expenses provided to Indemnitor and reasonably
incurred by the Indemnitee pursuant to this Section 9.4(c) shall be promptly reimbursed by the
Indemnitor unless the claim in the Third Party Claim Notice is a Contested Claim, which shall be
resolved in accordance with Section 9.8. In the event any lawsuit is commenced by the Indemnitee
to enforce its rights under this Section 9.4(c) and the Indemnitee prevails in such action, the
Indemnitor shall reimburse the Indemnitee for the Indemnitee’s reasonable legal fees and other
reasonable litigation expenses incurred in connection therewith.

     9.5 Limitation on Liability; Claims Period.

          (a) Limitation. Buyer’s right to recover from Seller for damages under Section 9.1
will be limited to [. . . *** . . .] in the aggregate; provided, however, that such
limitation shall not apply to claims brought by Buyer against Seller for fraud or pertaining to the
Excluded Liabilities, for which Buyer’s right to obtain recovery from Seller shall be unlimited.
Seller shall not have any liability under Section 9.1 unless the aggregate amount of damages
exceeds [. . . *** . . .] (the “Threshold”) and, in such event Seller shall be required to
pay damages from the first dollar after [. . . *** . . .] and [. . . *** . . .] shall be a
deductible that is not recoverable; provided however, that the Threshold shall not
apply to claims brought by Buyer against Seller for fraud or pertaining to the Excluded
Liabilities. Buyer and Seller each acknowledge and agree that, from and after the Closing, their
sole and exclusive remedy with respect to the breaches of representations and warranties and
covenants contained in this Agreement shall be pursuant to the indemnification provisions set forth
in this Article 9. Notwithstanding the foregoing, the parties shall be entitled to equitable
remedies in connection with breach of covenants contained in this Agreement or any Transaction
Agreement.

          (b) No Consequential Damages, Etc. Notwithstanding anything to the contrary set
forth herein, in no event shall either party hereto have any liability for consequential,
incidental, special or punitive damages incurred by an Indemnitee; provided that amounts awarded to
third parties or paid by an Indemnitee in settlement of a Third Party Claim, including the
foregoing types of damages that are paid by the Indemnitee, shall be considered direct damages of
the Indemnitee for which it will be entitled to indemnification from the Indemnitor.

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 24 -

 

     9.6 Third Party Recoveries; Other. If Seller makes a payment with respect to any
claim under the representations or warranties set forth in this Agreement and Buyer subsequently
receives from a third party or under the terms of any insurance policy a sum in respect of the same
claim, then Buyer shall repay to Seller such amounts as is equal to the sum subsequently received,
up to, but not exceeding, the full amount paid by Seller to Buyer with respect to such claim. If
Buyer receives a third party recovery prior to Seller making payment in respect of the claim to
which such third party recovery pertains, then such recovery shall be deducted from any damages
subject to indemnification under this Agreement with respect to such claim. If any potential
indemnification claim arises by reason of a liability which is contingent only, then Buyer shall
not be under any obligation to make any payment pursuant to such indemnification claim until such
time as the contingent liability ceases to be contingent and becomes actual; provided,
however, that if any Indemnitee makes a provisional claim against Seller for
indemnification based on a contingent liability within the time periods for such claims to be made
as set forth in this Agreement, and the claim does not become actual until after such time period,
the Indemnitee shall be entitled to indemnification for such claim in accordance with the terms of
this Agreement and shall be entitled to adjust the amount of its claim for indemnification once its
actual losses and liabilities are known. Seller’s representations and warranties set forth in this
Agreement are made exclusively to Buyer and are not transferable or assignable, and no third party
shall rely thereon; provided, however, that Buyer may assign its rights under this
Article 9, including but not limited to the right to be indemnified by Seller for losses and
liabilities attributable to breaches by Seller of its representations and warranties hereunder, to
any party to whom Buyer sells or transfers the Business or all or substantially all of the Assets.

     9.7 Effect of Indemnification. All indemnification payments under Sections 9.1 and
9.2 will be deemed adjustments to the Purchase Price except as otherwise may be required by
applicable tax law.

     9.8 Resolution of Disputed Indemnification Claim. Each indemnification claim given by
the Indemnitee shall be resolved as follows:

          (a) If, within [. . . *** . . .] after an Indemnification Notice or Third Party Claim Notice
is received by the Indemnitee, the Indemnitor does not contest such notice in writing to the
Indemnitee, the Indemnitor shall be conclusively deemed to have consented to the recovery by the
Indemnitee of the full amount of damages (subject to the limits contained in this Article 9)
specified in the Indemnification Notice or Third Party Claim Notice in accordance with this Article
9, and, without further notice, to have stipulated to the entry of a final judgment for damages
against the Indemnitor for such amount in any court having jurisdiction over the matter where venue
is proper.

          (b) If the Indemnitor gives the Indemnitee written notice contesting all or any portion of an
indemnification claim (a “Contested Claim”) within the [. . .***. . .] period specified in
Section 9.8(a) above, then such Contested Claim shall be resolved by either (i) a written
settlement agreement or memorandum executed by the Indemnitee and the Indemnitor or (ii) in the
absence of such a written settlement agreement within [. . .***. . .] following receipt by the
Indemnitee of the Contested Claim from the Indemnitor, by binding arbitration between the

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 25 -

 

Indemnitee and the Indemnitor in accordance with the terms and provisions of Section 11.7
below.

ARTICLE 10 CERTAIN POST-CLOSING COVENANTS.

     10.1 Hired Employees

          (a) At the Closing, Buyer shall offer employment to all of the employees identified on
Schedule 1.10, including those on vacation and those on leave of absence who are entitled
by law to return to their employment following such leave of absence, who were actively employed by
Seller immediately prior to the date hereof and any replacement employees hired with the consent of
Buyer following the date hereof. Those employees identified on Schedule 1.10 shall be
offered employment with Buyer in positions at least comparable to their positions with Seller prior
to the Closing and with compensation and benefits [. . . *** . . .]to those applicable to such
employees prior to the Closing. With respect to Buyer’s welfare or benefits plans, Buyer shall use
commercially reasonable efforts to ensure that the service of Hired Employees with Seller shall
apply for eligibility, vesting, contributions, sharing and entitlement to benefits under Buyer’s
welfare or benefits plans.

          (b) With respect to each welfare plan of Buyer in which the Hired Employees become
participants, Buyer shall use commercially reasonable efforts to (i) cause there to be waived any
pre-existing condition, domestic partner or eligibility limitations and (ii) give effect, in
determining any deductible and maximum out-of-pocket limitations for the current year, to claims
incurred and amounts paid by, and amounts reimbursed to, the Hired Employees under similar plans
maintained by Seller immediately prior to the Closing.

          (c) Buyer shall not assume any liabilities or obligations for the provision of notice or
payment in lieu of notice or any applicable penalties with respect to Hired Employees or any other
employees of the Seller of its Affiliates under the Worker Adjustment and Retraining Notification
Act (the “WARN Act”) or any similar state or local law arising as a result of the
transactions contemplated by this Agreement. Notwithstanding the foregoing, for a period of 60
days following the Closing, Buyer shall not cause any of the Hired Employees to suffer “employment
loss” for purposes of the WARN Act to the extent such employment loss could reasonably be expected
to create a WARN Act-related liability for Seller, unless Buyer has a good reason for terminating
any such employee, including but not limited to, violation of Buyer’s employee policies, theft or
violation of law.

          (d) Buyer shall assume and provide to the Hired Employees the [. . . *** . . .].

     10.2 Books and Records: Access.

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 26 -

 

          (a) Buyer acknowledges that Seller may keep duplicate copies of any books and records
pertaining to the Business that also may pertain to the Excluded Assets. Unless otherwise
consented to in writing by Seller, for a period of [. . . *** . . .] after the Closing, Buyer shall
not destroy, alter or otherwise dispose of any original books or records of the Business included
in the Assets without first offering to surrender such books and records to Seller and shall
maintain such books and records in good condition in a reasonably accessible location. Buyer shall
allow Seller reasonable access during normal business hours to examine and copy such books and
records, subject to Seller treating all information contained therein as strictly confidential and
proprietary information of Buyer which Seller may not disclose to any third party or use for any
purpose other than defense of any litigation pertaining to Seller’s operation of the Business or
ownership of the Assets prior to Closing or preparation of tax returns.

          (b) Unless otherwise consented to in writing by Buyer, for a period of [. . . *** . . .] after
the Closing, the Seller shall not destroy, alter or otherwise dispose of any original books or
records of the Business without first offering to surrender such books and records to Buyer and
shall maintain such books and records in good condition in a reasonably accessible location. The
Seller shall allow Buyer reasonable access during normal business hours to examine and copy such
books and records.

ARTICLE 11 MISCELLANEOUS MATTERS.

     11.1 Survival of Representations and Warranties. All representations and warranties
shall survive the Closing for a period of [. . . *** . . .], provided that (i) any representations
and warranties of Seller herein regarding [. . . *** . . .] shall survive the Closing for a period
of [. . . *** . . .] and (ii) there shall be no limit on the time in which an Indemnitee hereunder
may make a claim against an Indemnitor hereunder for fraud. In addition, Buyer may make claim for
indemnification with regard to matters involving Seller’s [. . . *** . . .] any time during a
period of [. . . *** . . .] following the Closing. No claim for indemnification shall be brought
against an Indemnitor after the date of expiration of such representation or warranty specified in
this Section 11.1, provided, however, the Indemnitor will be responsible for claims
set forth in an Indemnification Notice delivered prior to the foregoing expiration dates, even if
such claims are not resolved until after the expiration dates.

     11.2 Further Assurances; Access to Records. At any time and from time to time after
the Closing Date, at the request of Buyer and without further consideration, Seller shall execute,
acknowledge and deliver all such further documents, and shall do and perform all such further acts
and deeds, as may reasonably be requested to more effectively vest in Buyer the rights and benefits
intended to be conferred hereby and to consummate more effectively the transactions contemplated
hereby.

     11.3 Amendments, Waivers. This Agreement may not be changed in any manner except by a
written agreement signed by all parties. The failure of any party to enforce at any time any of the
provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor
in any way effect the validity of this Agreement or any part thereof or the right of any party
thereafter to enforce each and every such provision. No waiver of any breach

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 27 -

 

of this Agreement shall be held to be a waiver of any other or subsequent breach. All waivers
shall be in writing and executed by the party to be charged therewith.

     11.4 Expenses. Buyer and Seller shall each be responsible for and bear all of its own
costs and expenses (including without limitation attorneys’ fees and costs, accountants’ fees and
costs, other professionals’ fees and costs) incurred in connection with the negotiation,
preparation, execution and delivery of this Agreement and the Transaction Agreements and the
consummation of the proposed transactions described herein and therein.

     11.5 Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed to be an original, but all of such counterparts together shall be deemed
to be one and the same instrument.

     11.6 Contents of Agreement; Parties in Interest; Assignment, Etc. 

          (a) This Agreement, including the Schedules hereto and the Transaction Agreements, closing
certificates and other documents referred to herein, sets forth the entire understanding and
agreement of the parties hereto with respect to the subject matter hereof. All previous
agreements, promises, representations, commitments and understandings, whether verbal or written,
between the parties regarding the subject matter hereof are merged into and superseded by this
Agreement. All representations, warranties, covenants, terms and conditions of this Agreement
shall be binding upon and inure to the benefit of and be enforceable by the respective legal
representatives, successors and permitted assigns of the parties hereto. Nothing contained in this
Agreement, express or implied, is intended to confer upon any Person or entity other than the
parties hereto and their respective successors and permitted assigns any rights or remedies under
or by reason of this Agreement or any Transaction Agreement.

          (b) This Agreement may not be assigned by either party hereto without the prior written
consent of the other party, except that Buyer may assign this Agreement to an Affiliate of Buyer so
long as Buyer and Buyer’s parent continue to be bound by its obligations hereunder.

     11.7 Dispute Resolution.

          (a) Arbitration. In the event any dispute, claim, question or difference between the
parties (a “Dispute”) arises with respect to this Agreement or its performance,
enforcement, breach, termination or validity, the parties shall use all commercially reasonable
efforts to settle the Dispute. To this end, they shall consult and negotiate with each other, in
good faith and understanding of their mutual interests, to reach a just and equitable solution
satisfactory to all parties. If the parties do not reach a solution to the Dispute within a period
of [. . . *** . . .] following the first written notice of the Dispute by any party to the other,
then upon written notice by any party to the other, the Dispute may be submitted to arbitration in
accordance with the rules of the American Arbitration Association then in effect based upon the
following:

               (i) the arbitration tribunal shall consist of [. . . *** . . .] appointed by mutual agreement
of the parties;

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 28 -

 

               (ii) the arbitration award shall be given in writing and shall be final and binding on the
parties, and shall deal with the question of costs of arbitration and all related matters;

               (iii) judgment upon any award may be entered in any court having jurisdiction or application
may be made to the court for a judicial recognition of the award or an order of enforcement, as the
case may be;

               (iv) the arbitrator shall decide any dispute in accordance with the law governing this
Agreement, including equity, and may order specific performance, injunctions and other equitable
remedies; and

               (v) the arbitration will be held in San Diego, California.

          (b) Notwithstanding the commencement of arbitration under this Section 11.7, at any time
either party may proceed directly to a court of competent jurisdiction for any available injunctive
or other equitable remedy. The parties agree that irreparable damage may occur and that the
parties may not have any adequate remedy at law in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the parties may be entitled to an injunction or injunctions to
prevent breaches of this Agreement and to enforce specifically the terms and provisions of this
Agreement in any federal or state court located in the State of California, this being in addition
to any other remedy to which they are entitled at law or in equity.

          (c) If any legal action, arbitration or other proceeding is brought for the enforcement of
this Agreement, or because of any alleged dispute, breach, default or misrepresentation in
connection with any of the provisions of this Agreement, the successful or prevailing party shall
be entitled to recover reasonable attorneys’ fees and other costs incurred therein, in addition to
any other relief to which it or they may be entitled. The court or arbitrator shall consider, in
determining the prevailing party, (x) which party obtains relief which most nearly reflects the
remedy or relief which the parties sought, and (y) any settlement offers made prior to commencement
of the trial in the proceeding. For any legal proceeding instituted hereunder, the parties consent
to the exclusive venue of the state and federal courts located in San Diego, California.

     11.8 Article and Section Headings and Gender. The Article and Section headings herein
have been inserted for convenience of reference only and shall in no way modify or restrict any of
the terms or provisions hereof. All references in this Agreement to Articles, Sections and
Schedules refer to Articles, Sections and Schedules to this Agreement. The use of masculine or any
other pronoun herein when referring to any party is for convenience only and shall be deemed to
refer to the particular party intended regardless of the actual gender of such party.

     11.9 Schedules. The Schedules to this Agreement shall be construed with and as an
integral part of this Agreement to the same extent as if the same had been set forth verbatim
herein.

- 29 -

 

     11.10 Notices. All notices, consents, waivers or other communications which are
required or permitted hereunder shall be in writing and shall be sufficient if delivered personally
(including by means of an internationally recognized courier service for which a written receipt is
given) or by registered or certified mail, return receipt requested, postage prepaid, or by
facsimile transmission providing a receipt, as follows (or to such other address as shall be set
forth in a notice given in the same manner):

	 	 	 
	If to Buyer:

	 	If
to Seller:

	 
	 	 
	Pharmexa Inc.
	 	 
	c/o Pharmexa A/S

	 	IDM Pharma
	Kogle Allé 6

	 	9 Parker, Suite 100
	DK-2970 Hørsholm

	 	Irvine, CA 92618
	Fax: +45 4516 2500

	 	Fax: (949) 470-6470
	Attn: President

	 	Attn: Jean-Loup Romet-Lemonne, M.D.
	 
	 	 
	With a copy to:

	 	With a copy to:
	 
	 	 
	Nordlicht & Hand

	 	Cooley Godward LLP
	645 Fifth Avenue

	 	4401 Eastgate Mall
	New York, New York 10022

	 	San Diego, California 92121-1909
	Fax: (212) 421-0499

	 	Fax: (858) 550-6420
	Attn: Brian M. Hand, Esq.

	 	Attn: Barbara L. Borden, Esq.

All such notices shall be deemed to have been given on the date personally delivered, upon
possession of a receipt establishing a facsimile transmission was received, or five (5) days after
being mailed in the manner provided above.

     11.11 Separability. If any provision of this Agreement is found to be invalid,
illegal or unenforceable, the balance of this Agreement shall remain in effect. In the event the
invalid, illegal or unenforceable provision is material in the context of this Agreement, the
parties shall in good faith agree to a mutually satisfactory replacement which accomplishes, to the
extent possible, the original business purpose and intent of the invalid, illegal or unenforceable
provision in a valid and enforceable manner.

     11.12 Governing Law. This Agreement shall be construed and enforced in accordance
with the laws of the State of California without giving effect to the principles of conflicts of
laws.

     11.13 Confidentiality. Except as otherwise required by applicable laws or regulations
or otherwise provided by the terms of this Agreement, Seller and Buyer each agrees to, and to cause
their respective Affiliates, employees, counsel and agents to keep confidential all non-public
information relating to the Assets, the Assumed Liabilities, Business and the confidential
information of the other party, except in the event the same becomes generally available to the
public through no breach of this Section. The obligations of the parties under this Section 11.13
shall survive the Closing for a period of [. . . *** . . .].

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

- 30 -

 

     11.14 Public Announcements. Except as the other party hereto shall authorize in
writing or as required by law, the parties hereto shall not disclose any matter or matters relating
to this transaction to any person not a Representative of such party. The Buyer and Seller shall
agree about the content of any statement or communication to the public or the press prior to
issuing any statement or communication to the public or the press regarding transactions
contemplated by this Agreement.

     11.15 Termination. This Agreement may be terminated and the transactions contemplated
by this Agreement may be abandoned at any time prior to the Closing Date (a) by mutual consent of
Seller and Buyer; or (b) by either Seller or Buyer if the Closing has not occurred on or prior to
January 1, 2006 if the party seeking termination is not then in material breach of its
representations, warranties or covenants in this Agreement. Nothing in this Section 11.15 shall be
deemed to release either party from any liability for material breach by such party of the terms
and conditions of this Agreement.

     11.16 Mutual Drafting. This Agreement has been subject to discussion and negotiation
by the parties with the assistance of their respective counsel and will not be interpreted or
construed by or for either of them by reason of the authorship thereof

- SIGNATURES APPEAR ON THE NEXT PAGE -

- 31 -

 

EXECUTION PAGE

ASSET PURCHASE AGREEMENT

     IN WITNESS WHEREOF, this Agreement has been executed as of the day and year first above
written.

	 	 	 	 	 	 	 
	 	 	IDM PHARMA, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Emile Loria	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Emile Loria	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	President and CEO	 	 
	 
	 	 	 	 	 	 
	 	 	PHARMEXA INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ W. Marc Hertz	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	W. Marc Hertz	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	CEO	 	 

- 32 -

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Eligible	 	 	Eligible	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Accrued	 	 	Accrued	 	 	Severance	 	 	Severance	 
	Name	 	Job title	 	 	Hire Date	 	 	Salary	 	 	Vacation	 	 	Personal Time	 	 	(Months)	 	 	(Dollars)	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	(1)	 	Hired Employee referenced in Section 7.8.

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 1.15. Excluded Equipment.

Software-

[. . . *** . . .]

Hardware-

[. . . *** . . .]

	 	 	 
	Schedule 1.15

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 1.27(ii). Intellectual Property Assets.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 1.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 2.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 3.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 4.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 5.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 6.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	 	 	Case Nos.	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	Subject Matter	 	in Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(ii)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 7.

 

Schedule 1.27(iv). Intellectual Property Assets.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	Matter	 	 	 	 	 	Case Nos. in	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	No.	 	Subject Matter	 	 	Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . .***. . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(iv)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 1.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	Matter	 	 	 	 	 	Case Nos. in	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	No.	 	Subject Matter	 	 	Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . .***. . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(iv)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 2.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	Matter	 	 	 	 	 	Case Nos. in	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	No.	 	Subject Matter	 	 	Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . .***. . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(iv)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 3.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	Matter	 	 	 	 	 	Case Nos. in	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	No.	 	Subject Matter	 	 	Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . .***. . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(iv)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 4.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Application/	 	 	 	 
	Matter	 	 	 	 	 	Case Nos. in	 	 	 	 	 	 	 	 	 	 	Patent/Publn.	 	 	Issue or	 
	No.	 	Subject Matter	 	 	Family	 	 	Title	 	 	Case Status	 	 	No.	 	 	Publn. Date	 
	[. . .***. . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.27(iv)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 5.

 

Schedule 1.28. Excluded Inventory.

     None.

	 	 	 
	Schedule 1.28

	 	 

 

 

Schedule 1.36. PADRE Technology Patents.

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Application/	 	Issue or
	 	 	 	 	 	 	 	 	Patent/	 	Publn.
	Subject Matter	 	Case Nos. in Family	 	Title	 	Case Status	 	Publn. No.	 	Date
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.36

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Application/	 	Issue or
	 	 	 	 	 	 	 	 	Patent/	 	Publn.
	Subject Matter	 	Case Nos. in Family	 	Title	 	Case Status	 	Publn. No.	 	Date
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 

	 	 	 
	Schedule 1.36

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 1.39. Additional Permitted Liens.

     None.

	 	 	 
	Schedule 1.39

	 	 

 

 

Schedule 2.1(g). Permits.

[. . . *** . . .]

	 	 	 
	Schedule 2.1(g)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 3.1. Tax Allocation.

Reference is made to Section 3.1 of the Asset Purchase Agreement between IDM Pharma Inc. and
Pharmexa Inc pursuant to which the cash portion of the Purchase Price plus the Assumed Liabilities
will be allocated among the Assets for tax purposes as set forth in this Schedule 3.1 (defined
terms refer to the Asset Purchase Agreement):

	 	 	 	 	 	 	 	 	 
	Asset Type	 	Asset Class	 	 	Amount	 
	[. . . *** . . .]
	 	 	 	 	 	 	—	 

	 	 	 
	Schedule 3.1

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 4.2(b). Required Consents, Licenses or Authorizations of Government Authorities.

[. . . *** . . .]

	 	 	 
	Schedule 4.2(b)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 4.5(a). Material Contracts and Required Consents for Material Contracts.

Material Contracts Not Requiring Consent:

[. . . *** . . .]

	 	 	 
	Schedule 4.5(a)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 1.

 

[. . . *** . . .]

Material Contracts Requiring Consent:

[. . . *** . . .]

	 	 	 
	Schedule 4.5(a)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 1.

 

[. . . *** . . .]

	 	 	 
	Schedule 4.5(a)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Page - 1.

 

Schedule 4.5(c). Authorized Funding Remaining Under NIH Grants.

IDM Pharma, Inc. – Infectious Disease Contracts/Grants with the NIH through October 31, 2005.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Potential	 
	Contract	 	 	 	 	 	Funding	 	 	Billing	 	 	Balance	 	 	Additional	 
	Number	 	Contract Name	 	 	(to date)	 	 	(to date)	 	 	to bill	 	 	Funding*	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	*	 	Provided for informational purposes only. Actual funding will depend upon government funding.
Seller makes no representation with respect to any actual future funding that may be provided by
the NIH.

	 	 	 
	Schedule 4.5(c)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 4.6(a).

List of Registered Intellectual Property Assets

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Filing	 	 	 	 	 	 	Reg.	 	 	Status &	 
	Matter No.	 	Trademark	 	 	Country	 	 	Date	 	 	Reg. No.	 	 	Date	 	 	Remarks	 
	[. . . *** . . .]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

[. . . *** . . .]

Licenses and Rights to Intellectual Property Assets and Programs

[. . . *** . . .]

	 	 	 
	Schedule 4.6(a)

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

 

 

Schedule 4.11. Events Since September 30, 2005.

None.

	 
	Schedule 4.11

 

 

Schedule 6.6. Consents Required to Close.

[. . . *** . . .]

	 	 	 
	 

	 	*Confidential Treatment Requested
   under
17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2(b)(1)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]